TRI Pollution Prevention Report for POLYPEPTIDE LABORATORIES INC. and N,N-Dimethylformamide

Facility ID: 9050WPLYPP365MA

Facility Name and Address:
POLYPEPTIDE LABORATORIES INC.
365 MAPLE AVE
TORRANCE, CA 90503

Parent Company: POLYPEPTIDE LABORATORIES INC

Industry: Pharmaceutical Preparation Manufacturing (325412)
Chemical: N,N-Dimethylformamide

Production Related Waste Management for Selected Chemical


lchemid=0000068122
    Waste Management Comparison - 2019



Pollution Prevention Activities for Selected Chemical


Reporting Year Section 8.10: Newly Implemented Source Reduction Activity Section 8.10: Methods to Identify Activity Section 8.11: Optional Pollution Prevention Information*
2022 Source Reduction:: S21: Optimized process conditions to increase efficiency
Methods to Identify SR Opportunities: T04: Participative team management
2021 Source Reduction:: S21: Optimized process conditions to increase efficiency

Methods to Identify SR Opportunities: T01: Internal pollution prevention opportunity audit(s)
Methods to Identify SR Opportunities: T04: Participative team management
S21: PolyPeptide has an active ongoing program to optimize the utilization of Dimethylformamide.

2020 Source Reduction:: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis

Methods to Identify SR Opportunities: T01: Internal pollution prevention opportunity audit(s)
Methods to Identify SR Opportunities: T04: Participative team management
2019 Source Reduction:: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis

Methods to Identify SR Opportunities: T04: Participative team management
Methods to Identify SR Opportunities: T01: Internal pollution prevention opportunity audit(s)
W50: Dimethylformamide (DMF) is largest volume solvent that the PolyPeptide (PPL) Group currently employs in its manufacturing process. Through a combination of better washing efficiency, reuse and process analytics PPL aims to reduce DMF consumption by >25%.

Source Reduction - Dimethylformamide (DMF) is largest volume solvent that the PolyPeptide (PPL) Group currently employs in its manufacturing process. Through a combination of better washing efficiency, reuse and process analytics PPL aims to reduce DMF consumption by >25%.
2018 Barriers: B5-Barriers to P2 B5 - Specific regulatory/permit burdens.

Barriers to P2: B5 - Specific regulatory/permit burdens. - FDA approved production process. Changes must be approved by FDA.

2016 Source Reduction:: W32: Improved procedures for loading, unloading, and transfer operations
Methods to Identify SR Opportunities: T10: Vendor assistance
2015 Source Reduction:: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis[-0-4%]
Methods to Identify SR Opportunities: T04: Participative team management
Source Reduction - Our clients are changing their BOC chemistry to FMOC chemistry where possible at the outset of drug development which can reduce certain hazardous reactants with less hazardous reactants..
2014 Source Reduction:: W15: Introduced an in-line product quality monitoring or other process analysis system
Methods to Identify SR Opportunities: T01: Internal pollution prevention opportunity audit(s)
2013 Source Reduction:: W19: Other changes in operating practices


Methods to Identify SR Opportunities: T04: Participative team management
Methods to Identify SR Opportunities: T06: Employee recommendation (under a formal company program)
Methods to Identify SR Opportunities: T11: Other
W19: The company is utilizing lean manufacturing principles.

Source Reduction - Continuous improvement is encouraged in all work procedures.
Source Reduction - Daily production scheduling meetings are held to address immediate concerns in addition to weekly project meetings which are held to plan longer term projects and actions.
Barriers to P2 - Recycling statements for TRI section 8.11Polypeptide Laboratories produces customized Polypeptides for drug formulation for major pharmaceutical corporations. Each formulation requires pure reagents, thus no recycling can be attempted for reagents.
2012 Source Reduction:: W19: Other changes in operating practices


Methods to Identify SR Opportunities: T04: Participative team management
Methods to Identify SR Opportunities: T06: Employee recommendation (under a formal company program)
Methods to Identify SR Opportunities: T11: Other
W19: Implementation of lean manufacturing to optimize operation cost and bottle necks in production workflow

Source Reduction - Continuous improvement
Source Reduction - Suggestions on increasing production efficiency
Source Reduction - Internal meeting to optimize operation costs, reduce waste and costs
*Classifications of Optional Pollution Prevention Information shown in brackets are provided by EPA.


TRI Pollution Prevention Glossary

The Waste Management Hierarchy

The waste management hierarchy established by the Pollution Prevention Act (PPA) guides waste generators toward the best options for managing wastes. The preferred option is to prevent pollution at its source, but for waste that is generated, the preferred management methods are recycling, followed by burning for energy recovery, treatment and, as a last resort, disposing of the waste.
  • Source Reduction includes activities that eliminate or reduce the generation of chemical waste.
  • Recycling includes the recovery of a toxic chemical in waste for reuse.
  • Energy Recovery includes the combustion of toxic chemicals in waste to generate heat or electricity.
  • Treatment includes the destruction of a toxic chemical in waste.
  • Disposal or Other Releases includes toxic chemical quantities entering the environment.
The PPA requires facilities to provide the following details about each chemical they report to TRI:
Facilities may also provide optional Pollution Prevention Information describing their source reduction, recycling, or pollution control activities.